Analyst firms · Guggenheim · ORIC
Guggenheim ORIC price target and rating history
Oric Pharmaceuticals Inc. (ORIC) · Health Care
Guggenheim rates Oric Pharmaceuticals Inc. (ORIC) Buy with a $18 price target, as of its latest action on Sep 4, 2025. It has published 3 rating actions on ORIC since March 2022, including 1 upgrade and 1 downgrade. Across 6 firms with a ORIC price target in the last 12 months, the median target is $23.50.
- Current rating
- Buy
- Price target
- $18
- Median target, all firms
- $23.50
- Actions on ORIC
- 3
Guggenheim price target on ORIC
Every Guggenheim rating on ORIC
- Sep 4, 2025
- Mar 21, 2023
- Mar 22, 2022
How other firms rate ORIC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Outperform | $26 | Oct 5, 2026 |
| BTIG | Buy | $26 | Sep 23, 2026 |
| Stifel | Buy | $14 | Jun 12, 2026 |
| Goldman Sachs | Buy | $15 | May 15, 2026 |
| Piper Sandler | Overweight | $22 | Jan 7, 2026 |
| Evercore ISI | Outperform | $25 | Nov 20, 2025 |
| Wolfe Research | Peer Perform | Nov 18, 2025 |
Questions about Guggenheim and ORIC
- What is Guggenheim's price target for ORIC?
- Guggenheim's latest stated price target for Oric Pharmaceuticals Inc. (ORIC) is $18, from its action on Sep 4, 2025.
- What is Guggenheim's rating on ORIC?
- Guggenheim rates ORIC Buy, a bullish rating, as of Sep 4, 2025.
- When did Guggenheim last change its view on ORIC?
- On Sep 4, 2025, Guggenheim resumes coverage at Buy, price target $18.
- How does Guggenheim's ORIC target compare with other analysts?
- Across 6 firms with a ORIC price target in the last 12 months, the median target is $23.50.
More ORIC rating histories
All Guggenheim ratingsORIC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.